Allogene Therapeutics ALLO Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Prepaid Expense and Other Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's increase (decrease) in prepaid expense and other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's increase (decrease) in prepaid expense and other assets?
- Allogene Therapeutics (ALLO) reported increase (decrease) in prepaid expense and other assets of -$1.13M in Q1 2026.
- How has Allogene Therapeutics's increase (decrease) in prepaid expense and other assets changed year-over-year?
- Allogene Therapeutics's increase (decrease) in prepaid expense and other assets decreased by 281.7% year-over-year, from $623K to -$1.13M.
- What is the long-term trend for Allogene Therapeutics's increase (decrease) in prepaid expense and other assets?
- Over 2 years (2021 to 2025), Allogene Therapeutics's increase (decrease) in prepaid expense and other assets has grown at a 0.6% compound annual growth rate (CAGR), from -$3.2M to -$3.24M.
- What does increase (decrease) in prepaid expense and other assets mean?
- This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.